Crispr/cas-related methods and compositions for knocking out c5
US-2024415980-A1 · Dec 19, 2024 · US
Assays for IGFBP7 having improved performance in biological samples
US9822172B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9822172-B2 |
| Application number | US-201415035205-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 6, 2014 |
| Priority date | Nov 6, 2013 |
| Publication date | Nov 21, 2017 |
| Grant date | Nov 21, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides IGFBP7 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow test devices.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated antibody comprising a light chain variable region having an amino acid sequence of SEQ ID NO: 9 and a heavy chain variable region having an amino acid sequence of SEQ ID NO: 10. 2. An antibody according to claim 1 , wherein the antibody is a monoclonal antibody. 3. A nucleic acid, the sequence of which encodes an antibody comprising a light chain variable region having an amino acid sequence of SEQ ID NO: 9 and a heavy chain variable region having an amino acid sequence of SEQ ID NO: 10. 4. An antibody-expressing cell line, the cell line expressing an antibody comprising a light chain variable region having an amino acid sequence of SEQ ID NO: 9 and a heavy chain variable region having an amino acid sequence of SEQ ID NO: 10. 5. An isolated antibody comprising a light chain variable region having an amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region having an amino acid sequence of SEQ ID NO: 12. 6. An antibody according to claim 5 , wherein the antibody is a monoclonal antibody. 7. A nucleic acid, the sequence of which encodes an antibody comprising a light chain variable region having an amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region having an amino acid sequence of SEQ ID NO: 12. 8. An antibody-expressing cell line, the cell line expressing an antibody comprising a light chain variable region having an amino acid sequence of SEQ ID NO: 11 and a heavy chain variable region having an amino acid sequence of SEQ ID NO: 12.
Assignees
Inventors
Classifications
related to diseases not provided for elsewhere · CPC title
Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy · CPC title
involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors} · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
characterized by their source of isolation or production · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9822172B2 cover?
- The invention provides IGFBP7 immunoassays with improved clinical performance, particularly when used in the evaluation of renal injuries. The immunoassays rely on the selection and use of antibodies and antibody pairs that exhibit improved assay performance when used in complex clinical specimens such as biological fluids, and particularly when used in rapid assay formats such as lateral flow …
- Who is the assignee on this patent?
- Astute Medical Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Nov 21 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).